Supports RFK JR. Research Research – not only for vaccines

Tiba Biotech, one of the targeted beneficiaries, had a tiba biotech contract, a $ 750,000 contract with cold that was scheduled to end on October 30. The company was developing a RNai -based treatment for H1N1 influenza, also known as swine flu. RNAI is short for RNA and indicates small pieces of RNA that can close the production of specific proteins. The approach is well studied, and many RNAI medications are on the market. The first was approved in 2018 to treat the damage of the nerves caused by a rare disease called genetic blood point disease by mediation.

The cancellation of the contract was a surprise for TIBA, which obtained a stopping order on August 5 and which did not indicate the activities of developing a flexible vaccine in Barda. “Our project does not include the development of a flexible product, which is a therapeutic treatment, not a vaccine.”

Government contracts often include specific landmarks that contractors must achieve to receive financing and move forward in their projects. Tiba says that her project has achieved its goals so far and was about to be completed.

Also among the canceled contracts, it was a $ 750,000 prize for Emori University to convert anti -virus -based antiviral therapy and Covid in the formulation of dry, inhaled powder. The project did not include the development of a vaccine. “Unfortunately, we do not have many ideas that we offer about canceling grants,” Emori spokesman Brian Katzitz said in an email.

The cuts are consistent with Kennedy’s desire to remove research in infectious diseases, though Experts warn They can leave the United States more vulnerable to future epidemics.

Despite the low infectious diseases related to RNA, the administration has expressed enthusiasm for some NGOs that involve us.

In January, shortly after assuming his post, President Trump announced a joint project by Openai, Oracle and SoftBank. At that time, Oracle CEO Larry Ellison talked about the possibility of artificial intelligence created custom vaccines based on cancer.

in August 12 In the Washington Post, the National Director of Health, Jay Bhatera, admitted the promise of the Mersal Rana. “I do not contradict its capabilities. In the future, it may be presented after breakthroughs in treating diseases such as cancer, and HHS is still investing in continuous research on applications in oncology and other complex diseases.”

Unlike his boss, Bahtasharia says he does not believe that flexible vaccines have caused great harm. But he says the reason for stopping the research of a flexible vaccine is that the platform lost the confidence of the public – the logical basis that deviates from Kennedy.

However, it may be more acceptable when it comes to treating patients with very genetic disorders.

Earlier this year, organizers in the FDA Greenlit is a dedicated genetics remedy For a baby named KJ MULDON with a rare liver disease and threatens life. It is created in only six months, and is used to provide genes editing ingredients to its liver. This was the first time that a treatment for genes was used to successfully treat the patient.

In June, Marti Macari’s Food and Drug Administration Commissioner He praised the achievement on Its podAnd described it as “a kind of great victory for medical science”, and in FDA round table Makari said the agency will continue to facilitate the organizational process of these types of products.

Researchers are behind the process of treating genes for the use of the same approach to more patients and recently met with the Food and Drug Administration on the proposal of the clinical experience. “FDA) was very positive about the proposal and has effectively gave us the green light to move forward in our work,” says Kiraan Musunuru, Professor of Translation Research at the University of Pennsylvania and the Children’s Hospital in Philadelphia.

The team has another meeting with the Food and Drug Administration within a month or two to discuss the extension of the concept of the platform beyond one disease or one gene to a broader set of disorders. He says, “We’ll see how things go.”